Meeting Reports 2002

SLE: Targets For New Therapeutics Outline

January 10-12, 2002 (historical)

Image of lupus brochure

A Scientific Conference
January 10-12, 2002
Hyatt Regency Bethesda
Bethesda, Maryland

S.L.E. Foundation, New York, NY

National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health

Sponsored by:

S.L.E. Foundation, Inc., New York, NY
National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD
Lupus Research Institute, New York, NY
Office of Research on Women's Health, NIH, Bethesda, MD
National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

Additional Financial Support by:

Merck & Company, Inc., Whitehouse Station, NJ

Organizers

Jane Salmon, M.D., Weill Medical College of Cornell University and Hospital for Special Surgery, New York, NY
David Wofsy, M.D., University of California and Veterans Administration Medical Center, San Francisco, CA
Margaret G. Dowd, S.L.E. Foundation, Inc., New York, NY
Susana Serrate-Sztein, M.D., and Elizabeth Gretz, Ph.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD

Purpose

The purpose of this conference, SLE: Targets for New Therapeutics, is to facilitate the exchange and integration of scientific information between scientists working in disparate areas relating to systemic lupus erythematosus (SLE), and to identify novel strategies for clinical intervention.

Major scientific advances on several fronts in recent years have important potential implications regarding SLE. These advances include progress in molecular biology, genetic mapping capabilities, understanding the mechanisms of tolerance, the events that signal apoptotic cell death, and mediators of tissue injury. It is necessary to integrate this information with new data on the genetics of autoimmunity and autoimmune-mediated tissue injury in order to identify factors that contribute to the initiation and progression of SLE. Thus, it seems particularly appropriate at this time to bring together both basic and clinical scientists working on the causes and cures for SLE.

This meeting will integrate new observations in the following five sessions:

  • Extrinsic and Intrinsic Triggers of Autoimmunity
  • Predisposing Factors: Genetics of SLE in humans
  • Immunoregulatory Mechanisms
  • Mediators of Tissue Injury
  • Novel Therapies

Posters and workshops will cover basic mechanisms, clinical features and epidemiology, and outcome measures. The evening plenary session is Drug Trials and Tribulations: Update on Clinical Trials in SLE. Registrants are invited to submit abstracts for poster and/or oral presentations related to these topics. The abstract deadline is December 10, 2001.

Presenters and Workshop Chairs

James Balow, M.D., National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
Timothy Behrens, M.D., University of Minnesota, Minneapolis, MN
Richard Burt, M.D., Northwestern University, Chicago, IL
Jill Buyon, M.D., New York University School of Medicine, Hospital for Joint Diseases, New York, NY
Joseph Craft, M.D., Yale School of Medicine, New Haven, CT
Lindsey Criswell, M.D., M.P.H., University of California, San Francisco, CA
Mary Crow, M.D., Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY
David Daikh, M.D., Ph.D., University of California and VA Medical Center, San Francisco, CA
Betty Diamond, M.D., Albert Einstein College of Medicine, Bronx, NY
Robert Eisenberg, M.D., University of Pennsylvania, Philadelphia, PA
Charles Esmon, Ph.D., Howard Hughes Medical Institute, Oklahoma Medical Research Foundation, Oklahoma City, OK
Valerie Fadok, D.V.M., Ph.D., National Jewish Medical and Research Center, Denver, CO
Mark Ginsberg, M.D., Scripps Research Institute, La Jolla, CA
Dafna Gladman, M.D., Toronto Hospital, Western Division, Toronto, Canada
Jane Gross, Ph.D., ZymoGenetics, Seattle, WA
Jose-Carlos Gutierrez-Ramos, Ph.D., Millenium Pharmaceuticals, Inc., Cambridge, MA
Bevra Hahn, M.D., UCLA School of Medicine, Los Angeles, CA
John Harley, M.D., Ph.D., Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Michael Holers, M.D., University of Colorado, Denver, CO
David Horowitz, M.D., University of Southern California, Los Angeles, CA
Judith James, M.D., Ph.D., Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Daniel Kastner, M.D., Ph.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Brian Kotzin, M.D., University of Colorado Health Sciences Center, Denver, CO
Matthew Liang, M.D., M.P.H., Harvard Medical School, Boston, MA
Peter E. Lipsky, M.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Michael Lockshin, M.D., Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY
John O'Shea, M.D., National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Michelle Petri, M.D., Johns Hopkins Hospital, Baltimore, MD
David Pisetsky, M.D., Ph.D., Duke University Medical Center, Durham VA Hospital, Durham, NC
Richard Quigg, M.D., University of Chicago, Chicago, IL
Rosalind Ramsey-Goldman, M.D., Dr.P.H., Northwestern University Medical School, Chicago, IL
Westley Reeves, M.D., University of Florida, Gainesville, FL
Jane Salmon, M.D., Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY
Katherine Siminovitch, M.D., University of Toronto, Mount Sinai Hospital and University Health Network, Toronto, Canada
Betty Tsao, Ph.D., UCLA School of Medicine, Los Angeles, CA
Edward Wakeland, Ph.D., University of Texas Southwestern Medical Center, Dallas, TX
Mark Walport, M.D., Imperial College School of Medicine, Hammersmith Hospital, London, UK
David Wofsy, M.D., University of California, San Francisco, CA

Agenda

SLE: Targets for New Therapeutics
A Scientific Conference
January 10-12, 2002

Program - Thursday, January 10, 2002

7:45-8:30 a.m. Registration and Coffee

8:30 a.m. Welcome Address: Jane Salmon

8:40 a.m.-12:00 noon: Session I: Extrinsic and Intrinsic Triggers of Autoimmunity

Chair: David Pisetsky

  • David Pisetsky - The role of bacterial DNA in triggering anti-DNA production in SLE
  • Judith James -The role of EBV infection in the pathogenesis of SLE
  • Michael Lockshin - Speculations about the role of sex in SLE
  • Valerie Fadok - The interaction of apoptotic cells with the immune system
  • Westley Reeves - The pristane model of SLE

1:30-5:30 p.m. Session II: Predisposing Factors: Genetics of SLE in Humans

Chair: Brian Kotzin

  • Brian Kotzin - Identification of genes that promote murine lupus
  • Edward Wakeland - Identification of genes that suppress murine lupus
  • Mark Walport - SLE: A disease of disordered waste disposal
  • Timothy Behrens - Genetic fine mapping in human SLE
  • Lindsey Criswell - ACE polymorphisms in human SLE: importance of genetic heterogeneity
  • John Harley - Clinical variation holds genetic secrets of lupus
  • Betty Tsao - Follow-up linkage studies in SLE

7:30-9:30 p.m. Evening Posters and Workshops

Basic mechanisms
Clinical features and epidemiology
Outcome measures

Program- Friday, January 11, 2002

8:30 a.m.-12:00 noon Session III: Immunoregulatory Mechanisms

Chair: Katherine Siminovitch

  • Bevra Hahn - Immunoregulatory abnormalities in SLE
  • Katherine Siminovitch - Roles of SH2 domain containing tyrosine phosphatases in modulating lymphocyte activation
  • Joseph Craft - Mechanisms of loss of T cell tolerance in SLE
  • John O'Shea - Cytokine signaling and immunodeficiency
  • Jane Gross - Role of BLyS and its receptors TAC1 and BCMA in B cell development and regulation of autoimmune disease
  • Peter Lipsky - B cells in SLE

2:00- 5:30 p.m. Session IV: Mediators of Tissue Injury

Chair: Jane Salmon

  • Jane Salmon - Complement activation as a mediator of anti-phospholipid antibody-induced injury
  • Betty Diamond - A model for CNS injury in SLE
  • Mark Ginsberg - Alpha 4 integrins and leukocyte trafficking
  • Charles Esmon - Thrombosis as a target of inflammatory-mediated injury
  • Jose-Carlos Gutierrez-Ramos - Genomic approaches for identifying mediators of tissue injury
  • Daniel Kastner - Mendelian disorders of inflammation

7:30-9:30 p.m. Evening Plenary Session:

Drug Trials and Tribulations: Update on Clinical Trials in SLE

Program - Saturday, January 12, 2002

8:30 a.m.-12:00 noon Session V: Novel Therapies

Chair: David Wofsy

  • James Balow - Cytotoxic therapy for lupus nephritis
  • David Daikh - Targeting active immune responses in SLE by inhibition of T cell costimulation
  • Robert Eisenberg - Targeting B cells in SLE
  • Richard Quigg - Treatment of SLE by inhibition of complement activation
  • Michelle Petri - High-dose cyclophosphamide for SLE
  • Richard Burt - Stem cell replacement in SLE

Conference Logistics

Hotels in the area

We strongly recommend that you make your hotel arrangements as soon as possible at our conference site:

Hyatt Bethesda
1 Bethesda Metro Center
Bethesda, MD 20814
(301) 657-1234
$119.00, single occupancy (rates are subject to change without notice)

Deadline for reservations: December 17, 2001
Blocks of rooms have been reserved at these hotels (use code "lupus meeting" for special reservation rate).

Travel

By Air: Most major airlines serve the Washington metropolitan area via Ronald Reagan Washington National Airport, Dulles International Airport, and Baltimore-Washington International Airport. Travel time from all three airports to the hotel can take up to 1 to 1½ hours. Ground transportation is available from and to all three airports.

By Metro: The Hyatt Regency Bethesda is located at the Bethesda stop on the Red Line of the Metrorail subway system. The Hyatt is adjacent to the station.

By Car:

  • From the north, take I-95 South to I-495 West toward Silver Spring. Take Exit 34, Wisconsin Avenue (355 South) toward Bethesda. Follow Wisconsin Avenue for about 2 miles. The Hyatt Regency is on the right.
  • From the south, take I-95 North to I-495 toward Rockville and Silver Spring. At the split between I-495 and I-270, bear right to stay on I-495. Take the second exit, Wisconsin Avenue (355 South), toward Bethesda. Follow Wisconsin Avenue for about 2 miles. The Hyatt Regency is on the right.
  • From the west, take I-66 East to I-495 toward Rockville and Silver Spring. At the split between I-495 and I-270, bear right to stay on I-495 and take the second exit, Wisconsin Avenue (355 South), toward Bethesda. Follow Wisconsin Avenue for about 2 miles. The Hyatt Regency is on the right.
  • From the northwest, take I-270 South to I-495 East. Take the exit for Wisconsin Avenue (355 South) toward Bethesda. Follow Wisconsin Avenue for about 2 miles. The Hyatt Regency is on the right.

If you require more detailed directions, please contact the Hyatt Regency Bethesda at (301) 657-1234

Parking

The self-parking fee for Hyatt Regency hotel guests is $10/night, $12 for valet. The self-parking fee for non-hotel guests is $5/hour or a max of $10/day.

Maps of the Metrorail subway system and the Bethesda area can be accessed at http://www.nih.gov/about/maps.html.

Photographers and Videotaping

Photographers and videotape technicians will be present for much of the meeting. Participants may be photographed and videotaped to record and possibly broadcast the conference.

The registration fee is $100, which includes admission to the conference, coffee breaks, and evening snacks. Registration also includes breakfast, lunch, and dinner at the meeting site January 10 and 11, and breakfast only on January 12. We strongly encourage you to register early because space at the Hyatt Regency Hotel is limited. You may register by completing the registration form and returning it by regular mail, fax, or e-mail. Electronic access to the form and other information in this brochure is available at http://www.niams.nih.gov/News_and_Events/Meetings_and_Events/Reports/2002/lupusmtg.asp

Deadline for registration is December 19, 2001. In the event of a cancellation, a full refund will be made if written notice is received by December 19, 2001.

Method of Payment
Check (make check payable to the S.L.E. Foundation, Inc.)
Charge: Visa _______ Mastercard_______American Express_______
Card Number ___________________________________________________
Expiration Date __________________ Signature___________________

The information you provide will be listed on a roster of people registered for the meeting; please print if you complete this form by hand.

Return to:
Courtesy Associates, Inc.
Attn: SLE Conference
2000 L Street, N.W., Suite 710
Washington, DC 20036
Telephone: (202) 973-8680
Fax: (202) 331-0111

An asterisk (*) indicates required fields.

*Name_______________________________________________________________
Degrees_____________________________________________________________
Position_____________________________________________________________
*Institution_________________________________________________________
*Address____________________________________________________________
*City_______________________*State___________*Zip Code___________
*Phone No.____________________Fax No.____________________________
E-Mail_______________________________________________________

Check-in for registrants will begin on Thursday, January 10, at 7:45 a.m. at the Hyatt Regency Hotel.

Note: The Hyatt Regency Hotel is fully accessible for special accommodation needs. Please contact Pam Adewunmi, at (301) 594-5032, fax (301) 480-4543, e-mail adewunmp@mail.nih.gov. For additional information about the conference, call Courtesy Associates at (202) 973-8680 or e-mail NIAMS@courtesyassoc.com.

Abstracts: Submission Deadline Is December 10, 2001

Abstracts must be typed in a 5¾ inches by 5¾ inches format using a 12-point font with no more than 30 lines. Please select the workshop/poster session most appropriate for your abstract and identify the workshop on the 31st line in Bold as one of the following: 1) Basic Mechanisms, 2) Clinical Features and Epidemiology, or 3) Outcome Measures. All abstracts will be reviewed for poster presentations.

Travel grants: Twenty travel grants will be awarded to students and fellows based on abstracts. Please identify if first author is a student or fellow by placing an asterisk next to the name.

Abstract submissions may be made via e-mail to NIAMS@courtesyassoc.com. Please mention "Abstract Submission" in your subject line. Abstracts may also be submitted by mail addressed to:

Courtesy Associates
Attn: SLE Conference
2000 L St., N.W., Suite 710
Washington, DC 20036
Telephone: (202) 973-8680
Fax: (202) 331-0111

Sign language interpreters will be provided.